“Value Doesn’t Run April to April” – Prof Andrew Stradling on NHS’s New Value Based Procurement Pilots

Key Takeaways

• Current NHS pilots rely on easy‑to‑measure clinical metrics, not patient priorities
• Patient‑defined outcomes vary by age, condition, and care pathway
• Annual April‑to‑April budget cycles block multi‑year value investments
• SMEs should highlight immediate cost or capacity gains and use Innovator Passport
• Local clinician‑finance dialogue is essential for true value‑based procurement

Pulse Analysis

Value‑based procurement is reshaping how the NHS evaluates medical technology, moving beyond traditional cost‑per‑episode metrics toward a holistic view of patient outcomes. While infection rates and readmission figures are straightforward to quantify, they miss the nuanced benefits patients value—returning to work, maintaining independence, and avoiding long‑term side effects. By integrating patient‑reported outcome measures (PROMs) and experience metrics (PREMs) tailored to specific conditions, trusts can build evidence that aligns financial decisions with real‑world health gains. This shift demands richer data infrastructure and condition‑specific pathways, but promises more sustainable spending and higher satisfaction.

For small and medium‑sized enterprises (SMEs) entering the UK health market, the evolving framework presents both challenges and opportunities. Decision‑makers are under pressure to demonstrate immediate financial impact, so SMEs must articulate clear cost‑saving or productivity benefits—such as reduced nursing hours or shorter hospital stays—while simultaneously gathering longer‑term outcome data. Tools like the Innovator Passport streamline evidence submission across multiple trusts, mitigating the costly duplication that previously favored larger suppliers. Early clinician partnerships further refine value propositions, turning technical advantages into measurable pathway improvements that resonate with finance directors.

Cultural transformation hinges on bridging the gap between clinicians, procurement teams, and finance leaders. The entrenched annual budget cycle forces short‑term thinking, discouraging investments whose savings accrue beyond the fiscal year. Empowering finance directors to make multi‑year commitments enables genuine dialogue about long‑term value, while local leadership ensures that procurement policies reflect the realities of each patient cohort. Overcoming the April‑to‑April budgeting silo is the single biggest structural hurdle; without it, the NHS risks perpetuating a fragmented, cost‑driven approach that stifles innovation and overlooks what patients truly value.